4D Molecular Therapeutics Inc Capital Reinvestment Ratio
4D Molecular Therapeutics Inc capital reinvestment ratio. 4D Molecular Therapeutics Inc (FDMT) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow ($28.55 Million) in capital expenditures ($631.00K). Check FDMT cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of 4D Molecular Therapeutics Inc (2017–2017)
Capital reinvestment ratio of 4D Molecular Therapeutics Inc from 2017 to 2017. This chart tracks 4D Molecular Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Also explore 4D Molecular Therapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
4D Molecular Therapeutics Inc Capital Reinvestment Ratio by Year (2017–2017)
4D Molecular Therapeutics Inc capital reinvestment ratio by year from 2017 to 2017. For the full cash flow conversion analysis, see how efficiently does 4D Molecular Therapeutics Inc generate cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2017 | 0.07x | $8.24 Million | $573.00K | — |